Recent studies have focused on the convergence of GLP-1|GIP|glucagon receptor stimulant therapies and dopaminergic communication. While GCGR activators are commonly employed for addressing type 2 diabetes mellitus, their potential effects on reward circuits, specifically influenced by DA pathways